Epix gets FDA OK for Vasovist

By AuntMinnie.com staff writers

December 23, 2008 -- MRI contrast developer Epix Pharmaceuticals of Lexington, MA, has received approval from the U.S. Food and Drug Administration (FDA) to market its blood pool MR angiography contrast agent.

Vasovist is intended for use in evaluating aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease. AIOD occurs when iliac arteries become narrowed or blocked, potentially preventing the sufficient transport of oxygen and blood throughout the body.

Vasovist becomes the first contrast agent to be approved for marketing in the U.S. for use with MR angiography. The agent is already approved for marketing in 34 countries outside the U.S.

Epix reduces its workforce, October 23, 2008

Epix to form technology advisory board, August 14, 2008

Epix's Q2 results show boosted revenues, August 7, 2008

Epix secures equity financing, August 5, 2008

Epix CEO resigns, July 28, 2008

Copyright © 2008 AuntMinnie.com


To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking